ClinicalTrials.gg
CompletedNCT02183675Updated Nov 30, 2016Results posted

Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers

A Phase 1 interventional study of Telmisartan/Amlodipine and Telmisartan/Amlodipine/HCTZ in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Japan. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-30.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Male
01

Study summary

To assess drug drug interaction through pharmacokinetics investigation at steady state of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) given as three different formulations in healthy Japanese male subjects

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Japanese male subjects age >=20 and \<=35 years; body weight: >=50 kg and \<=80 kg; : >=18.0 and \<=25.0 kg/m2
  • Without any findings and complications on the basis of a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR), body temperature), 12-lead (ECGs), clinical laboratory tests
  • Signed and dated written prior to admission to the trial in accordance with the Good Clinical Practice (GCP) and the local legislation.

Exclusion criteria

Exclusion criteria:

  • Any finding of the medical examination (including BP, PR and ECGs) deviating from normal and of clinical relevance.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    T/A/H

    Telmisartan/Amlodipine/HCTZ fixed-dose combination

    Drug: Telmisartan/Amlodipine/HCTZ

  • Active comparator
    T/A

    Telmisartan/Amlodipine fixed-dose combination

    Drug: Telmisartan/Amlodipine

  • Active comparator
    T/H

    Telmisartan/HCTZ fixed-dose combination

    Drug: Telmisartan/HCTZ

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Measured Concentration (Cmax) at Steady State for Telmisartan

    Maximum measured concentration (Cmax) of telmisartan in plasma at steady state over the dosing interval tau

    Time frame: 15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h and 72h after 10 days drug administration

  2. Area Under the Plasma Concentration Curve at Steady State for Telmisartan

    Area under the plasma concentration curve (AUC) of telmisartan in plasma at steady state over the dosing interval tau

    Time frame: 15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h and 72h after 10 days drug administration

  3. Maximum Measured Concentration (Cmax) at Steady State for Amlodipine

    Maximum measured concentration (Cmax) of amlodipine in plasma at steady state over the dosing interval tau

    Time frame: 15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h, 96h, 120h and 144h after 10 days drug administration

  4. Area Under the Plasma Concentration Curve at Steady State for Amlodipine

    Area under the plasma concentration curve (AUC) of amlodipine in plasma at steady state over the dosing interval tau

    Time frame: 15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h, 96h, 120h and 144h after 10 days drug administration

  5. Maximum Measured Concentration (Cmax) at Steady State for HCTZ

    Maximum measured concentration (Cmax) of HCTZ in plasma at steady state over the dosing interval tau

    Time frame: 15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h and 48h after 10 days drug administration

  6. Area Under the Plasma Concentration Curve at Steady State for HCTZ

    Area under the plasma concentration curve (AUC) of HCTZ in plasma at steady state over the dosing interval tau

    Time frame: 15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h and 48h after 10 days drug administration

Secondary outcomes

  1. Amount of HCTZ Excreted in Urine at Steady State From 0 to 24 Hours

    Amount of HCTZ excreted in urine over the time interval from 0 to 24 hours at steady state

    Time frame: 0-6 hours (h), 6-12h and 12-24h after drug administration on day 10

07

Results

Posted Nov 30, 2016

Participant flow

An open-label, randomised, six-sequence crossover design. Each participant received three treatments each for 10 days. There was no washout period between treatments.

Treatment Period 1 (10 Days)
Participant flow — Treatment Period 1 (10 Days)
MilestoneT80-A5-H12.5 / T80-H12.5 / T80-A5T80-H12.5 / T80-A5 / T80-A5-H12.5T80-A5 / T80-A5-H12.5 / T80-H12.5T80-A5 / T80-H12.5 / T80-A5-H12.5T80-A5-H12.5 / T80-A5 / T80-H12.5T80-H12.5 / T80-A5-H12.5 / T80-A5
Started666666
Completed666666
Not completed000000
Treatment Period 2 (10 Days)
Participant flow — Treatment Period 2 (10 Days)
MilestoneT80-A5-H12.5 / T80-H12.5 / T80-A5T80-H12.5 / T80-A5 / T80-A5-H12.5T80-A5 / T80-A5-H12.5 / T80-H12.5T80-A5 / T80-H12.5 / T80-A5-H12.5T80-A5-H12.5 / T80-A5 / T80-H12.5T80-H12.5 / T80-A5-H12.5 / T80-A5
Started666666
Completed666664
Not completed000002
Withdrew: Adverse event000002
Treatment Period 3 (10 Days)
Participant flow — Treatment Period 3 (10 Days)
MilestoneT80-A5-H12.5 / T80-H12.5 / T80-A5T80-H12.5 / T80-A5 / T80-A5-H12.5T80-A5 / T80-A5-H12.5 / T80-H12.5T80-A5 / T80-H12.5 / T80-A5-H12.5T80-A5-H12.5 / T80-A5 / T80-H12.5T80-H12.5 / T80-A5-H12.5 / T80-A5
Started666664
Completed666664
Not completed000000

Outcome measures

PrimaryMaximum Measured Concentration (Cmax) at Steady State for Telmisartan

Maximum measured concentration (Cmax) of telmisartan in plasma at steady state over the dosing interval tau

Time frame:
15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h and 72h after 10 days drug administration
Reported as:
Geometric mean · ng/mL
Maximum Measured Concentration (Cmax) at Steady State for Telmisartan
ng/mLT80-A5-H12.5T80-A5T80-H12.5
Maximum Measured Concentration (Cmax) at Steady State for Telmisartan970 ± 69.3857 ± 70.7895 ± 75.0
Statistical analysis
  • T80-A5-H12.5 vs T80-H12.5 · ANOVA · Adjusted geometric mean ratio (%): 108.39 · 90% CI 93.081 to 126.225Ratio calculated as T80-A5-H12.5 divided by T80-H12.5
  • T80-A5-H12.5 vs T80-A5 · ANOVA · Adjusted geometric mean ratio (%): 114.86 · 90% CI 98.216 to 134.326Ratio calculated as T80-A5-H12.5 divided by T80-A5
PrimaryArea Under the Plasma Concentration Curve at Steady State for Telmisartan

Area under the plasma concentration curve (AUC) of telmisartan in plasma at steady state over the dosing interval tau

Time frame:
15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h and 72h after 10 days drug administration
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration Curve at Steady State for Telmisartan
ng*h/mLT80-A5-H12.5T80-A5T80-H12.5
Area Under the Plasma Concentration Curve at Steady State for Telmisartan2510 ± 72.12570 ± 70.82580 ± 81.4
Statistical analysis
  • T80-A5-H12.5 vs T80-H12.5 · ANOVA · Adjusted geometric mean ratio (%): 97.53 · 90% CI 90.43 to 105.19Ratio calculated as T80-A5-H12.5 divided by T80-H12.5
  • T80-A5-H12.5 vs T80-A5 · ANOVA · Adjusted geometric mean ratio (%): 102.04 · 90% CI 96.94 to 107.40Ratio calculated as T80-A5-H12.5 divided by T80-A5
SecondaryAmount of HCTZ Excreted in Urine at Steady State From 0 to 24 Hours

Amount of HCTZ excreted in urine over the time interval from 0 to 24 hours at steady state

Time frame:
0-6 hours (h), 6-12h and 12-24h after drug administration on day 10
Reported as:
Geometric mean · mg
Amount of HCTZ Excreted in Urine at Steady State From 0 to 24 Hours
mgT80-A5-H12.5T80-H12.5
Amount of HCTZ Excreted in Urine at Steady State From 0 to 24 Hours10.4 ± 11.49.9 ± 12.2
Statistical analysis
  • T80-A5-H12.5 vs T80-H12.5 · ANOVA · Adjusted geometric mean ratio (%): 104.80 · 90% CI 101.949 to 107.734Ratio calculated as T80-A5-H12.5 divided by T80-H12.5
PrimaryMaximum Measured Concentration (Cmax) at Steady State for Amlodipine

Maximum measured concentration (Cmax) of amlodipine in plasma at steady state over the dosing interval tau

Time frame:
15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h, 96h, 120h and 144h after 10 days drug administration
Reported as:
Geometric mean · ng/mL
Maximum Measured Concentration (Cmax) at Steady State for Amlodipine
ng/mLT80-A5-H12.5T80-A5
Maximum Measured Concentration (Cmax) at Steady State for Amlodipine11.8 ± 21.811.3 ± 22.3
Statistical analysis
  • T80-A5-H12.5 vs T80-A5 · ANOVA · Adjusted geometric mean ratio (%): 103.95 · 90% CI 101.023 to 106.964Ratio calculated as T80-A5-H12.5 divided by T80-A5
PrimaryArea Under the Plasma Concentration Curve at Steady State for Amlodipine

Area under the plasma concentration curve (AUC) of amlodipine in plasma at steady state over the dosing interval tau

Time frame:
15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h, 96h, 120h and 144h after 10 days drug administration
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration Curve at Steady State for Amlodipine
ng*h/mLT80-A5-H12.5T80-A5
Area Under the Plasma Concentration Curve at Steady State for Amlodipine230 ± 23.4223 ± 21.8
Statistical analysis
  • T80-A5-H12.5 vs T80-A5 · ANOVA · Adjusted geometric mean ratio (%): 102.49 · 90% CI 100.167 to 104.867Ratio calculated as T80-A5-H12.5 divided by T80-A5
PrimaryMaximum Measured Concentration (Cmax) at Steady State for HCTZ

Maximum measured concentration (Cmax) of HCTZ in plasma at steady state over the dosing interval tau

Time frame:
15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h and 48h after 10 days drug administration
Reported as:
Geometric mean · ng/mL
Maximum Measured Concentration (Cmax) at Steady State for HCTZ
ng/mLT80-A5-H12.5T80-H12.5
Maximum Measured Concentration (Cmax) at Steady State for HCTZ107 ± 28.5102 ± 28.0
Statistical analysis
  • T80-A5-H12.5 vs T80-H12.5 · ANOVA · Adjusted geometric mean ratio (%): 105.35 · 90% CI 99.230 to 111.847Ratio calculated as T80-A5-H12.5 divided by T80-H12.5
PrimaryArea Under the Plasma Concentration Curve at Steady State for HCTZ

Area under the plasma concentration curve (AUC) of HCTZ in plasma at steady state over the dosing interval tau

Time frame:
15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h and 48h after 10 days drug administration
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration Curve at Steady State for HCTZ
ng*h/mLT80-A5-H12.5T80-H12.5
Area Under the Plasma Concentration Curve at Steady State for HCTZ584 ± 23.8565 ± 23.4
Statistical analysis
  • T80-A5-H12.5 vs T80-H12.5 · ANOVA · Adjusted geometric mean ratio (%): 103.39 · 90% CI 98.730 to 108.280Ratio calculated as T80-A5-H12.5 divided by T80-H12.5

Adverse events

Collected over 10 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T80-A5-H12.5—0/36 (0%)3/36 (8.3%)
T80-H12.5—0/36 (0%)3/36 (8.3%)
T80-A5—0/34 (0%)2/34 (5.9%)
All Patients—0/36 (0%)5/36 (13.9%)
Most frequent other events
Most frequent other events
EventT80-A5-H12.5T80-H12.5T80-A5All Patients
Alanine aminotransferase increasedInvestigations3/362/362/344/36
C-reactive protein increasedInvestigations1/361/360/342/36

Baseline characteristics

Treated set which included all subjects that were dispensed study drug and were documented to have taken at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)T80-A5-H12.5 / T80-H12.5 / T80-A5T80-H12.5 / T80-A5 / T80-A5-H12.5T80-A5 / T80-A5-H12.5 / T80-H12.5T80-A5 / T80-H12.5 / T80-A5-H12.5T80-A5-H12.5 / T80-A5 / T80-H12.5T80-H12.5 / T80-A5-H12.5 / T80-A5Total
Mean29.0 ± 4.927.3 ± 5.227.0 ± 4.225.8 ± 4.129.5 ± 5.129.3 ± 4.928.0 ± 4.6
Sex: Female, Male
Sex: Female, Male(Participants)T80-A5-H12.5 / T80-H12.5 / T80-A5T80-H12.5 / T80-A5 / T80-A5-H12.5T80-A5 / T80-A5-H12.5 / T80-H12.5T80-A5 / T80-H12.5 / T80-A5-H12.5T80-A5-H12.5 / T80-A5 / T80-H12.5T80-H12.5 / T80-A5-H12.5 / T80-A5Total
Female0000000
Male66666636
08

Study locations

1 site
  • 1348.5.001 Boehringer Ingelheim Investigational Site
    Kanagawa , Yokohama, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2014
First posted
Jul 8, 2014
Start
Jul 2014
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Nov 30, 2016
Last update
Nov 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02183675
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Jul 2014
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Nov 30, 2016
Last update
Nov 30, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Amlodipine · Hydrochlorothiazide

Start the discussion